Literature DB >> 29588670

Contemporary Antiplatelet Strategies in the Treatment of STEMI using Primary Percutaneous Coronary Intervention.

Sri Raveen Kandan1, Thomas W Johnson1.   

Abstract

Reperfusion therapy for patients presenting with an acute ST-segment elevation myocardial infarction (STEMI) involves primary percutaneous coronary intervention (PPCI) and concomitant oral antiplatelet and intravenous antithrombotic pharmacotherapy. There is a conflict between the desire to reduce the time between first medical contact and coronary re-canalisation and achieving effective platelet inhibition with oral antiplatelet agents. This review outlines the currently available antiplatelet treatments, and their place within the therapeutic timeline of a patient presenting with STEMI. Additionally, we focus on current challenges associated with effective antiplatelet treatment, including acute stent thrombosis (AST), the effect of morphine, platelet function assessment and concomitant anticoagulant therapy.

Entities:  

Keywords:  Primary percutaneous coronary intervention; ST-elevation myocardial infarction; antiplatelet therapy

Year:  2015        PMID: 29588670      PMCID: PMC5808489          DOI: 10.15420/icr.2015.10.1.26

Source DB:  PubMed          Journal:  Interv Cardiol        ISSN: 1756-1485


  43 in total

1.  Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) randomized study.

Authors:  Giuseppe Patti; György Bárczi; Dejan Orlic; Fabio Mangiacapra; Giuseppe Colonna; Vincenzo Pasceri; Emanuele Barbato; Béla Merkely; István Edes; Miodrag Ostojic; William Wijns; Germano Di Sciascio
Journal:  J Am Coll Cardiol       Date:  2011-10-04       Impact factor: 24.094

2.  A comparative bioavailability study of different aspirin formulations using on-line multidimensional chromatography.

Authors:  K A Sagar; M R Smyth
Journal:  J Pharm Biomed Anal       Date:  1999-11       Impact factor: 3.935

3.  Bivalirudin started during emergency transport for primary PCI.

Authors:  Philippe Gabriel Steg; Arnoud van 't Hof; Christian W Hamm; Peter Clemmensen; Frédéric Lapostolle; Pierre Coste; Jurrien Ten Berg; Pierre Van Grunsven; Gerrit Jan Eggink; Lutz Nibbe; Uwe Zeymer; Marco Campo dell' Orto; Holger Nef; Jacob Steinmetz; Louis Soulat; Kurt Huber; Efthymios N Deliargyris; Debra Bernstein; Diana Schuette; Jayne Prats; Tim Clayton; Stuart Pocock; Martial Hamon; Patrick Goldstein
Journal:  N Engl J Med       Date:  2013-10-30       Impact factor: 91.245

4.  Effect of platelet inhibition with cangrelor during PCI on ischemic events.

Authors:  Deepak L Bhatt; Gregg W Stone; Kenneth W Mahaffey; C Michael Gibson; P Gabriel Steg; Christian W Hamm; Matthew J Price; Sergio Leonardi; Dianne Gallup; Ezio Bramucci; Peter W Radke; Petr Widimský; Frantisek Tousek; Jeffrey Tauth; Douglas Spriggs; Brent T McLaurin; Dominick J Angiolillo; Philippe Généreux; Tiepu Liu; Jayne Prats; Meredith Todd; Simona Skerjanec; Harvey D White; Robert A Harrington
Journal:  N Engl J Med       Date:  2013-03-10       Impact factor: 91.245

5.  Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients.

Authors:  Melanie Gaubert; Marc Laine; Toesca Richard; Nathalie Fournier; Christophe Gramond; Jacques Bessereau; Zaïr Mokrani; Bruno Bultez; Virginie Chelini; Pierre Barnay; Luc Maillard; Franck Paganelli; Laurent Bonello
Journal:  Int J Cardiol       Date:  2014-02-22       Impact factor: 4.164

6.  Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial.

Authors:  Eva-Luise Hobl; Thomas Stimpfl; Josef Ebner; Christian Schoergenhofer; Ulla Derhaschnig; Raute Sunder-Plassmann; Petra Jilma-Stohlawetz; Christine Mannhalter; Martin Posch; Bernd Jilma
Journal:  J Am Coll Cardiol       Date:  2013-12-04       Impact factor: 24.094

Review 7.  Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist.

Authors:  Davide Capodanno; Kodlipet Dharmashankar; Dominick J Angiolillo
Journal:  Expert Rev Cardiovasc Ther       Date:  2010-02

8.  Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation.

Authors:  Nikolaus Sarafoff; Amadea Martischnig; Jill Wealer; Katharina Mayer; Julinda Mehilli; Dirk Sibbing; Adnan Kastrati
Journal:  J Am Coll Cardiol       Date:  2013-03-21       Impact factor: 24.094

Review 9.  Cangrelor: a review on its mechanism of action and clinical development.

Authors:  José Luis Ferreiro; Masafumi Ueno; Dominick J Angiolillo
Journal:  Expert Rev Cardiovasc Ther       Date:  2009-10

10.  Intravenous platelet blockade with cangrelor during PCI.

Authors:  Deepak L Bhatt; A Michael Lincoff; C Michael Gibson; Gregg W Stone; Steven McNulty; Gilles Montalescot; Neal S Kleiman; Shaun G Goodman; Harvey D White; Kenneth W Mahaffey; Charles V Pollack; Steven V Manoukian; Petr Widimsky; Derek P Chew; Fernando Cura; Ivan Manukov; Frantisek Tousek; M Zubair Jafar; Jaspal Arneja; Simona Skerjanec; Robert A Harrington
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

View more
  1 in total

Review 1.  Percutaneous pleural drainage in patients taking clopidogrel: real danger or phantom fear?

Authors:  Katherine Linder; Oleg Epelbaum
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.